Literature DB >> 841309

Interpreting cancer survival rates.

J E Enstrom, D F Austin.   

Abstract

Entities:  

Mesh:

Year:  1977        PMID: 841309     DOI: 10.1126/science.841309

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  9 in total

1.  The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer.

Authors:  G M Tsang; D C Watson
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

2.  Trends in cancer incidence, survival and mortality in northern Sweden 1960-1986.

Authors:  P Lenner; H Jonsson; O Gardfjell
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

3.  Breast cancer incidence and prevalence estimated from survival and mortality.

Authors:  R Capocaccia; A Verdecchia; A Micheli; M Sant; G Gatta; F Berrino
Journal:  Cancer Causes Control       Date:  1990-07       Impact factor: 2.506

4.  Examining survival data.

Authors:  A J Coldman; J M Elwood
Journal:  Can Med Assoc J       Date:  1979-10-20       Impact factor: 8.262

5.  What is progress against cancer?

Authors:  H O Adami
Journal:  Cancer Causes Control       Date:  1993-09       Impact factor: 2.506

6.  Cancer symptoms, clinical stage, and survival rates.

Authors:  D F Austin; J E Dunn
Journal:  Am J Public Health       Date:  1980-05       Impact factor: 9.308

7.  Methodological aspects on measurements of temporal trends in melanoma survival.

Authors:  R Bergström; M Thörn; H O Adami
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

8.  Components of small area variation in death rates: a method applied to data from Sweden.

Authors:  R Westerling
Journal:  J Epidemiol Community Health       Date:  1995-04       Impact factor: 3.710

9.  Socioeconomic differences in cancer survival.

Authors:  M Kogevinas; M G Marmot; A J Fox; P O Goldblatt
Journal:  J Epidemiol Community Health       Date:  1991-09       Impact factor: 3.710

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.